AI can help read CGM data for glucose forecasts, but broader health profiling still faces validation, privacy, and governance ...

DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis ...

June 11 (Reuters) - Drug wholesaler Pharmsource LLC said it was unaware the Dexcom (DXCM.O), opens new tab glucose sensors it bought from licensed distributors had been ‌slated for destruction, after ...

Add Yahoo as a preferred source to see more of our stories on Google. June 11 (Reuters) - Drug wholesaler Pharmsource LLC said it was unaware the Dexcom glucose ‌sensors it bought from licensed ...

Add Yahoo as a preferred source to see more of our stories on Google. Dexcom received FDA clearance for a 15-day version of its G7 continuous glucose monitor. (Courtesy of Dexcom) This story was ...

Every day there are new posts in a Facebook group — 89.5 thousand members strong — dedicated to Dexcom G7 issues and complaints. From inaccurate CGM readings and sensor failures to frustrating ...

Dexcom is transforming its Stelo CGM into a whole-family wellness device, securing FDA clearance for pediatric use and debuting new AI tools.

The CONNECT trial, presented at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans, found that 82% of adults with type 2 diabetes who used a Dexcom G7 improved their blood ...

Following expanded FDA approval for pediatric patients, the over-the-counter Stelo continuous glucose monitor is adding AI ...

AI may help smartwatches make glucose data more useful through better predictions, pattern detection, and personalized health ...

June 6 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not ...